Administration of ketamine, an antagonist of the N-methyl d-aspartate (NMDA) glutamate receptor, ameliorated PTSD-like behavior and led to reduced HCN1 expression and increased BDNF levels. This evidence concerns the gene HCN1 and post-traumatic stress disorder.